Europe - Germany • Industry focus
Linklaters
Linklaters' healthcare team is integrated into the global healthcare and life sciences group, thus covers cross-border matters, including transactions, restructuring and joint ventures. The practice is led by Jana Hager, who joined the partner roster in May 2023. Clients stem from the pharmaceutical, biotechnology, medical devices and healthcare services sectors and frequently instruct the team on interfacing corporate and M&A matters as well as regulatory issues in the area of product liability and safety, including related disputes, as well as compliance. Bolko Ehlgen and Julia Schönbohm both complement this offering with expertise in patent law as well as in the digital healthcare and data protection segments.
Legal 500 Editorial commentary
Work highlights
- Advising GlaxoSmithKline in a tender process for the award of a so-called pandemic preparedness contract, including negotiations with the Federal Republic of Germany, as well as advising on negotiations with the consortium partner CureVac. Additionally, advice on liability and exemption clauses in the pandemic preparedness contract.
- Advice to Carlyle and PAI Partners on the acquisition of Theramex, including regulatory advice relating to the investigation of regulatory compliance and product risks and the related contractual drafting.
- Advising Fresenius SE & Co. KGaA and its committees on the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA by means of a change of legal form into a stock corporation.
Practice head
The lawyer(s) leading their teams.
Jana Hager